377 related articles for article (PubMed ID: 1375718)
1. Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells.
Maroney AC; Qureshi SA; Foster DA; Brugge JS
Oncogene; 1992 Jun; 7(6):1207-14. PubMed ID: 1375718
[TBL] [Abstract][Full Text] [Related]
2. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
Tian M; Martin GS
Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
[TBL] [Abstract][Full Text] [Related]
3. Two novel variants of the v-src oncogene isolated from low and high metastatic RSV-transformed hamster cells.
Tatosyan A; Yatsula B; Shtutman M; Moinova E; Kaverina I; Musatkina E; Leskov K; Mizenina O; Zueva E; Calothy G; Dezélée P
Virology; 1996 Feb; 216(2):347-56. PubMed ID: 8607264
[TBL] [Abstract][Full Text] [Related]
4. The constitutive activation of the CEF-4/9E3 chemokine gene depends on C/EBPbeta in v-src transformed chicken embryo fibroblasts.
Gagliardi M; Maynard S; Bojovic B; Bédard PA
Oncogene; 2001 Apr; 20(18):2301-13. PubMed ID: 11402325
[TBL] [Abstract][Full Text] [Related]
5. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Kamps MP; Sefton BM
Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
[TBL] [Abstract][Full Text] [Related]
6. Mitogenesis of quiescent chick fibroblasts by v-Src: dependence on events at the membrane leading to early changes in AP-1.
Catling AD; Wyke JA; Frame MC
Oncogene; 1993 Jul; 8(7):1875-86. PubMed ID: 8510932
[TBL] [Abstract][Full Text] [Related]
7. Cloning of Rous sarcoma virus enhancer factor genes. II. RSV-EF-II, abundantly expressed in fibroblasts and muscle tissue, binds to an octamer sequence, 5'-GTACCACC-3', in the noncoding strand of RSV enhancer.
Cleavinger PJ; Shin BA; Kandala JC; Nambiar A; Swamynathan SK; Guntaka RV
Virology; 1996 Aug; 222(1):133-43. PubMed ID: 8806494
[TBL] [Abstract][Full Text] [Related]
8. Transformation of NIH3T3 cells by Rous sarcoma virus occurs with high efficiency in the absence of proviral rearrangements or amplification.
Falcone G; Provenzano C; Alemà S; Tatò F
Oncogene; 1992 Oct; 7(10):1913-20. PubMed ID: 1328985
[TBL] [Abstract][Full Text] [Related]
9. Evidence that a phosphotyrosine-containing 120,000 Da protein from Rous sarcoma virus-infected cells is phosphorylated by pp60v-src.
Lau AF
Oncogene Res; 1989; 4(3):185-94. PubMed ID: 2472591
[TBL] [Abstract][Full Text] [Related]
10. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
Lansing TJ; Turk BF; Kanner SB; Gilmer TM
Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
Hejnar J; Plachý J; Geryk J; Machon O; Trejbalová K; Guntaka RV; Svoboda J
Virology; 1999 Mar; 255(1):171-81. PubMed ID: 10049832
[TBL] [Abstract][Full Text] [Related]
12. Rous sarcoma virus does not induce sarcoma in early chick embryos by lack of the v-src gene expression.
Ogura H; Fujiwara T; Tanaka T
Cell Mol Biol (Noisy-le-grand); 1992; 38(5-6):477-82. PubMed ID: 1336425
[TBL] [Abstract][Full Text] [Related]
13. Intracellular targeting of pp60src expression: localization of v-src to adhesion plaques is sufficient to transform chicken embryo fibroblasts.
Liebl EC; Martin GS
Oncogene; 1992 Dec; 7(12):2417-28. PubMed ID: 1334249
[TBL] [Abstract][Full Text] [Related]
14. Transforming properties and substrate specificities of the protein tyrosine kinase oncogenes ros and src and their recombinants.
Jong SM; Zong CS; Dorai T; Wang LH
J Virol; 1992 Aug; 66(8):4909-18. PubMed ID: 1321277
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic protein p60v-src has competence activity but does not activate phosphatidylinositol turnover or protein kinase C in Balb/c 3T3 cells.
Han JW; Gaut J; Burstein E; Sadowski H; Young D; Macara IG
Oncogene; 1990 Apr; 5(4):467-74. PubMed ID: 2158036
[TBL] [Abstract][Full Text] [Related]
16. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.
Huang RP; Darland T; Okamura D; Mercola D; Adamson ED
Oncogene; 1994 May; 9(5):1367-77. PubMed ID: 8152797
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning of rat calpactin I heavy-chain cDNA whose expression is induced in v-src-transformed rat culture cell lines.
Ozaki T; Sakiyama S
Oncogene; 1993 Jun; 8(6):1707-10. PubMed ID: 8389036
[TBL] [Abstract][Full Text] [Related]
18. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Gelman IH; Khan S; Hanafusa H
Oncogene; 1993 Nov; 8(11):2995-3004. PubMed ID: 7692370
[TBL] [Abstract][Full Text] [Related]
19. Decrease in coupling of Gs in v-src-transformed NIH-3T3 fibroblasts: possible involvement of tyrosine phosphorylation of Gs by pp60v-src.
Akiho H; Tokumitsu Y; Noda M; Nomura Y
Arch Biochem Biophys; 1993 Jul; 304(1):235-41. PubMed ID: 7686735
[TBL] [Abstract][Full Text] [Related]
20. Analysis of phosphotyrosine-containing proteins present in v-src-infected myeloid progenitor cells.
Erwin JL; Anderson SM
Oncogene; 1992 Jun; 7(6):1101-7. PubMed ID: 1375716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
